Publications and Communications
Guidelines and Protocols
An assay guideline document is available which presents crucial issues for assay performance (ELISPOT, HLA-multimers) based on CIP proficiency panel experience and results.
Exemplary protocol for HLA-multimer staining (March 2011)
SOP for ELISPOT assay without serum, kindly provided by a high performer lab (March 2011)
Recommendations for long-term storage of MHC-multimer by freezing (Hadrup et al. Cytometry A, 87:37, 2015)
Guideline for Elispot plate reading (Janetzki et al. Nat Protocols 10:1098, 2015)
Consensus Ab panel for Treg detection (Santegoets et al. Cancer Immunol Immunother 64:1271-86, 2015) and comparison of Abs for CD127 staining (2018)
Harmonized protocol for TILs isolation and expansion (Hilf et al. Nature 565:240-45, 2019)
Reports from Proficiency Panels
Are available upon request:
Report CIP_ID18_2013_NK/E (phenotype and function of NK cells, -Feb 2014-)
Report CIP_ID15_2012_ELI/S (service panel, Elispot assay - Nov 2014-)
Report CIP_ID14_2012_ELIMUL/E (ELISPOT and HLA-multimer staining for in vitro expanded cells, 2nd phase ID11 -Dec 2012-)
Report CIP_ID13_2011_MUL/D (Multicolor HLA-multimer staining, 2nd phase of ID07 -Jan 2013-)
Report CIP_ID11_2011_ELIMUL/E (ELISPOT and HLA-multimer staining for in vitro expanded cells -April 2012-)
Report CIP_ID09_2010_ELI/S (ELISPOT -June 2011-)
Report CIP_ID08_2010_GAT/D (intracellular cytokine staining, gating -March 2011-)
Report CIP_ID07_2010_MUL/D (HLA-multimers -Oct 2010-)
Report CIP_ID06_2009_ICS/D (intracellular cytokine staining -March 2011-)
Report CIP_ID05_2008_ICS/D (intracellular cytokine staining -July 2009-)
Report CIP_ID04_2008_ELI/S (ELISPOT -Aug 2008-)
Report CIP_ID03_2008_MUL/S (HLA-multimers -Sept 2008-)
Report CIP_ID02_2006_ELIMUL/S (ELISPOT and HLA-multimers -Nov 2006-)
Report CIP_ID01_2005_ELIMUL/S (ELISPOT and HLA-multimers -Oct 2005-)
Original Articles
Hilf N,Hilf N, Kuttruff-Coqui S, […], Wick W. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019. 565:240-245.
Chandran PA, Laske K, Cazaly A, Rusch E, Schmid-Horch B, Rammensee HG, Ottensmeier CH, Gouttefangeas C. Validation of immunomonitoring methods for application in clinical studies: The HLA-peptide multimer staining assay. Cytometry B Clin Cyto. 2018 Mar;94(2):342-353. DOI. PMID.
Bidmon N, Kind S, Welters MJP, Joseph-Pietras D, Laske K, Maurer D, Hadrup SR, Schreibelt G, Rae R, Sahin U, Gouttefangeas C, Britten CM, van der Burg SH. Development of an RNA-based kit for easy generation of TCR-engineered lymphocytes to control T-cell assay performance. J. Immunol. Methods. 2018. 458:74-82. DOI. PMID.
Pedersen NW, Chandran PA, Qian Y, Rebhahn J, Petersen NV, Hoff MD, White S, Lee AJ, Stanton R, Halgreen C, Jakobsen K, Mosmann T, Gouttefangeas C, Chan C, Scheuermann RH, Hadrup SR. Automated Analysis of Flow Cytometry Data to Reduce Inter-Lab Variation in the Detection of Major Histocompatibility Complex Multimer-Binding T Cells. Front. Immunol. 2017. 8:858. DOI. PMID.
Mandruzzato S, Brandau S, Britten CM, Bronte V, Damuzzo V, Gouttefangeas C, Maurer D, Ottensmeier C, van der Burg SH, Welters MJ, Walter S. Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study. Cancer Immunol. Immunother. 2016. 65:161-9. DOI. PMID.
Santegoets SJ, Dijkgraaf EM, Battaglia A, Beckhove P, Britten CM, Gallimore A, Godkin A, Gouttefangeas C, de Gruijl TD, Koenen HJ, Scheffold A, Shevach EM, Staats J, Taskén K, Whiteside TL, Kroep JR, Welters MJ, van der Burg SH. Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunol. Immunother. 2015. 64:1271-86. DOI. PMID.
Janetzki S, Price L, Schroeder H, Britten CM, Welters MJ, Hoos A. Guidelines for the automated evaluation of Elispot assays. Nat. Protoc. 2015. 10:1098-115. DOI. PMID.
Bidmon N, Attig S, Rae R, Schröder H, Omokoko TA, Simon P, Kuhn AN, Kreiter S, Sahin U, Gouttefangeas C, van der Burg SH, Britten CM. Generation of TCR-engineered T cells and their use to control the performance of T cell assays. J. Immunol. 2015. 194:6177-89. DOI. PMID
White S, Laske K, Welters MJ, Bidmon N, van der Burg SH, Britten CM, Enzor J, Staats J, Weinhold KJ, Gouttefangeas C, Chan C. Managing Multi-center Flow Cytometry Data for Immune Monitoring. Cancer Inform. 2015. 13:111-22. DOI. PMID.
Gouttefangeas C, Chan C, Attig S, Køllgaard TT, Rammensee HG, Stevanović S, Wernet D, thor Straten P, Welters MJ, Ottensmeier C, van der Burg SH, Britten CM. Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters. Cancer Immunol. Immunother. 2015. 64:585-98. DOI. PMID.
Hadrup SR, Maurer D, Laske K, Frøsig TM, Andersen SR, Britten CM, van der Burg SH, Walter S, Gouttefangeas C. Cryopreservation of MHC multimers: Recommendations for quality assurance in detection of antigen specific T cells. Cytometry A. 2015. 87:37-48. DOI. PMID.
Chudley L, McCann KJ, Coleman A, Cazaly AM, Bidmon N, Britten CM, van der Burg SH, Gouttefangeas C, Jandus C, Laske K, Maurer D, Romero P, Schröder H, Stynenbosch LF, Walter S, Welters MJ, Ottensmeier CH. Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer staining. Cancer Immunol. Immunother. 2014. 63:1199-211. DOI. PMID.
Cron A, Gouttefangeas C, Frelinger J, Lin L, Singh SK, Britten CM, Welters MJ, van der Burg SH, West M, Chan C. Hierarchical modeling for rare event detection and cell subset alignment across flow cytometry samples. PLoS Comput. Biol. 2013. 9:e1003130. DOI. PMID
Filbert H, Attig S, Bidmon N, Renard BY, Janetzki S, Sahin U, Welters MJP, Ottensmeier C, van der Burg SH, Gouttefangeas C, Britten CM. Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols. Cancer Immunol. Immunother. 2012. 62:615-627. DOI. PMID.
Singh SK, Tummers B, Schumacher TN, Gomez R, Franken KL, Verdegaal EM, Laske K, Gouttefangeas C, Ottensmeier C, Welters MJ, Britten CM, van der Burg SH. The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study. Cancer Immunol. Immunother. 2012. 62:389-501. DOI. PMID.
Singh SK, Meyering M, Ramwadhdoebe TH, Stynenbosch LF, Redeker A, Kuppen PJ, Melief CJ, Welters MJ, van der Burg SH. The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools. Cancer Immunol. Immunother. 2012. 61:1953-1963. DOI. PMID.
Welters MJ, Gouttefangeas C, Ramwadhdoebe TH, Letsch A, Ottensmeier CH, Britten CM, van der Burg SH. Harmonization of the intracellular cytokine staining assay. Cancer Immunol. Immunother. 2012. 61:967-978. DOI. PMID.
Moodie Z, Price L, Gouttefangeas C, Mander A, Janetzki S, Löwer M, Welters MJ, Ottensmeier C, van der Burg SH, Britten CM. Response definition criteria for ELISPOT assays revisited. Cancer Immunol. Immunother. 2010. 59:1489-501. DOI. PMID
Mander A, Gouttefangeas C, Ottensmeier C, Welters MJ, Low L, van der Burg SH, Britten CM. Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program. Cancer Immunol. Immunother. 2010. 59:619-27. DOI. PMID.
Janetzki, S., Price, L., Britten, C. M., van der Burg, S. H., Caterini, J., Currier, J. R., Hoos, A. Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells. Cancer Immunology, Immunotherapy. 2010., 59(4), 609–618. DOI.
Britten CM, Gouttefangeas C, Welters MJ, Pawelec G, Koch S, Ottensmeier C, Mander A, Walter S, Paschen A, Müller-Berghaus J, Haas I, Mackensen A, Køllgaard T, thor Straten P, Schmitt M, Giannopoulos K, Maier R, Veelken H, Bertinetti C, Konur A, Huber C, Stevanović S, Wölfel T, van der Burg SH. The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol. Immunother. 2008. 57:289-302. DOI. PMID.
Comments / letters / reviews / book chapters
Britten CM, van der Burg SH, Gouttefangeas C. A framework for T cell assays. Oncotarget. 2015. 6:35143-4. DOI. PMID.
Kvistborg P, Gouttefangeas C, Aghaeepour N, Cazaly A, Chattopadhyay PK, Chan C, Eckl J, Finak G, Hadrup SR, Maecker HT, Maurer D, Mosmann T, Qiu P, Scheuermann RH, Welters MJ, Ferrari G, Brinkman RR, Britten CM. Thinking outside the gate: single-cell assessments in multiple dimensions. Immunity. 2015. 42:591-2. DOI. PMID.
Gouttefangeas C, Walter S, Welter MJP, Ottensmeier CH, van der Burg SH, Britten CM, Chan C. Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance and Future. Cancer Immunology: Translational Medicine from Bench to Bedside (ed. N Rezaei). Springer. Chapter 25: 471-486. 2015.
van der Burg SH, Walter S, Janetzki S, Britten CM, Galon J, Welters MJP, Gouttefangeas C Immunoguiding, the final frontier in the immunotherapy of cancer. (2014) In Cancer Immunotherapy meets oncology (CM Britten, S Kreiter, M. Diken & HG Rammensee eds). Springer International Publishing Switzerland p37-51 ISBN: 978-3-319-05103-1
Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJM, O’Donnell-Tormey J, Odunsi K, Old LJ, Ottenhoff THM, Ottensmeier C, Pawelec G, Roederer M, Roep BO, Romero P, van der Burg SH, Walter S, Hoos A, Davis MM. T Cell Assays and MIATA: The Essential Minimum for Maximum Impact Immunity 2012 Jul;37(1):37:1-2
Fox BA, et al. Defining the critical hurdles in cancer immunotherapy. J. Transl. Med. 2011. 9:214. DOI. PMID.
van der Burg SH, Kalos M, Gouttefangeas C, Janetzki S, Ottensmeier C, Welters MJP, Romero P, Britten CM, Hoos A. Harmonization of immune biomarker assays for clinical studies. Sci. Transl. Med. 2011. 3:108ps44. DOI. PMID.
Britten CM, Janetzki S, Gouttefangeas C, Welters MJ, Kalos M, Ottensmeier CH, Hoos A, van der Burg SH. T-cell immune monitoring assays to guide the development of new cancer vaccines. In Cancer Vaccines: From Research to Clinical Practice, by Adrian Bot, Mihail Obrocea, Francesco Marincola, C. Ed Informa Healthcare. September 2011
Britten CM, Janetzki S, van der Burg SH, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJM, O’Donnell-Tormey J, Odunsi K, Old LJ, Pawelec G, Roep BO, Romero P, Hoos A, Davis MM. Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol. Immunother. 2011. 60:15–22. DOI. PMID.
Frelinger J, Ottinger J, Gouttefangeas C, Chan C. Modeling flow cytometry data for cancer vaccine immune monitoring. Cancer Immunol Immunother. 2010. 59:1435-41. DOI. PMID..
Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, Melief CJ, Old LJ, Romero P, Hoos A, Davis MM. MIATA: Minimal Information About T cell Assays. Immunity. 2009. 31:527‐28. DOI. PMID.
Britten CM, Janetzki S, van der Burg SH, Gouttefangeas C, Hoos A. Toward the harmonization of immune monitoring in clinical trials: Quo vadis? Cancer Immunol. Immunother. 2008. 57:285-8. DOI. PMID.
A full text version of the article is available via Springer
van der Burg SH. Therapeutic Vaccines in Cancer, Moving from Immunomonitoring to Immunoguiding. Expert Review of Vaccines. 2008. 7:1-5. DOI. PMID.
CIMT Meeting Reports
Diken M, Chu KK, Brodsky AN. Translating Science into Survival: Report on the Third International Cancer Immunotherapy Conference. Cancer Immunol. Res. 2018. 6:10-13. DOI. PMID.
Kranz LM, Birtel M, Hilscher L, Grunwitz C, Petschenka J, Vascotto F, Vormehr M, Voss RH, Kreiter S, Diken M. CIMT 2016: Mechanisms of efficacy in cancer research – Report on the 14th Annual Meeting of the Association for Cancer Immunotherapy. May 10-12, 2016, Mainz, Germany. Hum. Vaccin. Immunother. 2016. 12:2805-12. DOI. PMID
Miller M, Jahndel V, Kutscher S, Mahr A, Rae R, Kloke BP. The right patient for the right therapy: 13th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 11-13, 2015. Cancer Immunol. Immunother. 2016. 65:1277-87. DOI. PMID.
Kranz L, Birtel M, Krienke C, Grunwitz C, Petschenka J, Reuter K, van de Roemer N, Vascotto F, Vormehr M, Kreiter S, Diken M. CIMT 2015: The right patient for the right therapy - Report on the 13th Annual Meeting of the Association for Cancer Immunotherapy. Hum. Vaccin. Immunother. 2015. 12:213-21. DOI. PMID.
Diken M, Boegel S, Grunwitz C, Kranz L, Reuter K, van de Roemer N, Vascotto F, Vormehr M, Kreiter S. CIMT 2014: Next waves in cancer immunotherapy - report on the 12th annual meeting of the Association for Cancer Immunotherapy. Hum. Vaccin. Immunother. 2015. 10:3090-100. DOI. PMID.
Kloke BP, Mahr A, Jabulowsky RA, Kutscher S, Rae R, Britten CM. Cancer immunotherapy achieves breakthrough status: 12th annual meeting of the association for cancer immunotherapy (CIMT), Mainz, Germany, May 6-8, 2014. Cancer Immunol. Immunother. 2014. 64:923-30. DOI. PMID.
Kloke BP, Rae R, Mahr A, Burkhardt UE, Kvistborg P, Britten CM. Towards the next waves of cancer immunotherapy: 11th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 14-16, 2013. Cancer Immunol. Immunother. 2013. 63:749-55. DOI. PMID.
Hobohm K, Seppmann T, Britten CM, Hoff H. Ninth annual meeting of the Association for Cancer Immunotherapy (CIMT 2011), May 25-27, 2011, Mainz, Germany. Cancer Immunol. Immunother. 2012. 61:137-43. DOI. PMID 7
Singh SK, Laske K, Gouttefangeas C, Britten CM, Welters MJ. CIMT 2010: report on the eighth annual meeting of the Association for Cancer Immunotherapy, May 26-28, 2010, Mainz, Germany. Cancer Immunol. Immunother. 2011. 60:443-50. DOI. PMID.
Diken M, Widenmeyer M, Gouttefangeas C, Welters MJ, Britten CM. CIMT 2009: report on the seventh annual meeting of the association for immunotherapy of cancer. June 3-5, Mainz, Germany. Cancer Immunol. Immunother. 2010. 59:1417-23. DOI. PMID.
Welters MJ, van Montfoort N, Khan S, Meyer RG, Britten CM. Report on the sixth annual meeting of the Association for Immunotherapy of Cancer (CIMT), May 15 and 16, 2008 in Mainz, Germany. Cancer Immunol. Immunother. 2009. 58:777-87. DOI. PMID.
Welters MJ, Gouttefangeas C, Attig S, Koch S, Britten CM. Report on the Fifth Annual Meeting of the Association for Immunotherapy of Cancer (CIMT) April 12-14, 2007 in Würzburg, Germany. Cancer Immunol. Immunother. 2008. 57:135-42. DOI. PMID.
Gouttefangeas C, Britten CM, Badalians ED, Pawelec G. CIMT meets strategies for immune therapy. Report and abstracts of the 4th International Meeting of the Association for Immunotherapy of Cancer, Mainz, Germany, 4-5 May 2006. Cancer Immunol. Immunother. 2007. 56:397-427. DOI. PMID.
Britten CM, Gouttefangeas C, Kreiter S. Cancer immunotherapy 2005: Mainz, Germany, 12-13 May 2005. Cancer Immunol. Immunother. 2006. 55:475-80. DOI. PMID.
Britten CM, Mueller L, Knights A, Pawelec G. Cancer Immunotherapy 2004: Mainz, Germany, 6-7 May 2004. Cancer Immunol. Immunother. 2004. 53:1153-8. DOI. PMID.
Meetings
2016
2nd Symposium on Advances in Cancer Immunology and Immunotherapy, 15-17 December 2016, Athens, Greece
2015
CIP in the European 7th framework project GAPVAC 27 October 2015, Mainz, Germany
CIP at the annual AACR meeting 18-22 April 2015, Philadelphia, USA
4th Cancer Immunotherapy and Immunomonitoring Conference (CITIM) 27–30 April 2015, Ljubljana, Slovenia – Oral presentation – Harmonization of immunomonitoring assays: the CIP experience
CIP in the European 7th framework project GAPVAC 27 October 2015, Mainz, Germany
2014
European Research Infrastructures for Poverty Related Diseases, November 17, 2014 – Oral presentation – Harmonization of the ICS and its application in immunotherapy of cancer patients
29th SITC Annual Meeting, November 7-9, 2014, National Harbor MD – Poster – Detection and functional assessment of regulatory T-cells in clinical samples
44rd Annual Meeting of the German Society for Immunology, September 17-20, 2014, Bonn, Germany – Joined satellite symposium CIMT-DGfI – Immune monitoring, new developments
CYTO2014, May 17-21, 2014, Ft. Lauderdale, Florida – Oral presentation – Thinking out of the gate
2013
13th Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS 2013), June 27-30, 2013, Boston, USA – Oral presentation – Cancer Immunotherapy Immunoguiding Program Update
CIC Scientific Colloquium “Entering the Era of Combination Therapies: Practical Implementation” April 25-27, 2013, Washington, USA – CIMT co-organization of Session 6: Immune monitoring – Oral presentations -
3rd Cancer Immunotherapy and Immunomonitoring Conference (CITIM) April 22-25, 2013, Poland – Poster – The Cancer Immunotherapy Immunoguiding Program (CIP): An international network for harmonizing immunological biomarkers in cancer immunotherapy
2012
20th Meeting DNA vaccines 2012, December 5-7, 2012, San Diego, USA – Oral presentation – Update on CIP and MIATA
Progress in Vaccination Against Cancer, PIVAC 12 meeting, September, 11-13 2012, Nottingham, UK – Poster -The Cancer Immunotherapy Immunoguiding Program (CIP): An international network for the harmonization of immune monitoring assays
CIC Scientific Colloquium “ immune signatures in the tumor and beyond: toward predictive and prognostic markers” April 19-21, 2012, National Harbor, USA- Oral presentation – Harmonizing immune monitoring T-cell assays, from cell samples to data analysis: recent proficiency panels of the Cancer Immunotherapy Immunoguiding Program (CIP)
27th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) October 26-28, 2012, North Bethesda, USA – Poster – Harmonization of immunological biomarkers by an international network: the Cancer Immunotherapy Immunoguiding Program (CIP)
40th congress of the International Society of Oncology and Biomarkers (ISOBM) October 13-17, 2012, Jerusalem, Israel – Oral presentation -. The Cancer Immunotherapy Immunoguiding Program (CIP):An international network for the harmonization of cellular immunological biomarkers
CIC Scientific Colloquium, Immune signatures in the tumor and beyond: toward predictive and prognostic markers” April 19-21, 2012, National Harbor, USA- Oral presentation – Harmonizing immune monitoring T-cell assays, from cell samples to data analysis: recent proficiency panels of the Cancer Immunotherapy Immunoguiding Program (CIP)
2011
ESCII/NIBIT Meeting New Perspectives in the Immunotherapy of Cancer, October 19-22, 2011, Siena, Italy – Oral presentation – Harmonization of immune biomarker assays - Towards enhanced quality and reproducibility in clinical studies
Progress in Vaccination Against Cancer, PIVAC 11 meeting, October 10-13, 2011, Copenhagen, Denmark – Poster - The Cancer Immunotherapy Immunoguiding Program (CIP): an international network for the harmonization of immune monitoring T-cell assays
CIMT Annual Meeting, May 25- 27, 2011, Mainz, Germany – Oral presentations – “CIP break-out session”
2010
Progress in Vaccination Against Cancer, PIVAC 10 meeting, September 27–30, 2010, Cambridge, UK – Oral presentation – “Harmonisation of T-cell assays for the monitoring of immunotherapeutic trials: update on the CIMT Immunoguiding program”
Biological Therapy of Cancer –from disease to targeted therapy 10th international symposium, September 8-10, 2010, Munich, Germany – Oral presentation – “Monitoring and immunoguiding of clinical vaccine trials”
CIMT Annual Meeting, May 26-28, 2010, Mainz, Germany – Oral presentations – “CIP short talk session”
2009
iSBTc-FDA-NCI Workshop on Prognostic and Predictive Immunologic Biomarkers in Cancer, October 28, 2009, Washington D.C., USA – Short oral introduction to – “The Cancer Immunotherapy Immunoguiding Program”
EORTC-GI group – Perspectives of Immunotherapy in GI cancer, October 15-16, 2009, Amsterdam, The Netherlands – Oral presentation – “Harmonized T-cell monitoring assays for immunotherapy trials”
Progress in Vaccination Against Cancer, PIVAC 9 meeting, October 8–10, 2009, Sofia, Bulgaria – Oral presentation – “Harmonized T-cell monitoring assays for immunotherapy trials. Update on the CIMT Immunoguiding Program”
CIMT, June 3-5, 2009, Mainz, Germany – Oral presentations – CIP late break-out session: new and ongoing panels (Multimers, ELISPOT, ICS)
2008
Joint ESCII Annual Meeting and PIVAC 8 meeting – Recent advances in cancer immunotherapy with an emphasis on cancer, October 9-10, 2008, Athens, Greece – Oral presentation – “Harmonisation of T-cell monitoring: Report on the activities of the CIMT monitoring panel initiative”
Cellular Mediated Immunity (CMI) standardization techniques in evaluation of vaccine response, September 15–17, 2008, Annency, France – Oral presentation – “Harmonization of T cell immunomonitoring within the CIMT Monitoring Panel – correct protocol choices and additional sources of variation”
Annual Meeting of the Cancer Reserch Institute: Cancer Immunology & Immunotherapy 2008: From Discovery to Development to Drug, September 15-17, 2008, New York, USA – Oral presentation – “Harmonized T-cell monitoring assays as biomarkers for immunotherapy trials: a data driven approach by the CIMT Immunoguiding program (CIP)“
9th International Conference on Chronic Myeloid and Lymphoid Malignancies, May 29-31, 2008, Kazimierz Dolny, Poland – Oral presentation – “Standardization of T cell immunomonitoring – protocol choices and additional sources of variation”
CIMT Annual Meeting, May 15 -16, 2008, Mainz, Germany – Oral presentations – “Updates on the CIMT immunomonitoring panel III (Multimers), panel IV (ELISPOT) and panel V (ICS)”
9th International Symposium Biological Therapy of Cancer / From Disease to Targeted Therapy, March 12-15 2008, Munich, Germany – Oral presentation – “Standardization of T-cell immunomonitoring – correct protocol choices and additional sources of variation”
MASIR 2008 – Measurement of Antigen-Specific Immune Responses, January 30 - February 2, 2008, La Plagne, France – Oral presentation – “The CIMT-Monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes”
2007
DC Thera Immunomonitoring Workshop, December 6-7, 2007, Brussels, Belgium – Oral presentations – “The CIMT-Monitoring panel: efforts towards the harmonization of T-cell monitoring”
Part 1: Harmonizing/Optimizing assay protocols
Part 2: Harmonization of additional aspects needed?
Cancer Vaccines Adjuvants & Delivery Systems – CVADD 2007 Conference, October 10-12, 2007, Heidelberg, Germany – Oral presentation – “The CIMT-Monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes”
CVC Colloquium and Annual Meeting, September 27-29, 2007, Washington, USA – Oral presentation – “First Harmonization Criteria for Cellular Immune Response Assays for Cancer Vaccine Trials – Results from Two Large Proficiency Panels”
CIMT Annual Meeting, April 12-14, 2007, Würzburg, Germany – Oral presentation – “Lessons learned from interlaboratory testing in phases I/2005 and II/2006″
2006
Symposium “The need for standardisation of Immune Competence Assessment and Monitoring”, October 16, 2006, Cardiff, Wales – Oral presentation – “Defining standardisation for immune monitoring”
CIMT Annual Meeting, May 4-5, 2006, Mainz, Germany – Poster abstract P04 – “The CIMT Monitoring Panel: Enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays”
Progress in Vaccination against Cancer 2006 – PIVAC 6 meeting, September 28-29, 2006, Granada, Spain – Oral presentation – “The CIMT monitoring panel: Standardization of in vitro methods for enumerating antigen specific CD8+ T lymphocytes”